Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is currently recruiting participants for a Phase 2 study titled ‘A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies in treating rheumatoid arthritis, a chronic inflammatory disease. The significance of this study lies in its potential to offer new treatment options for patients who have not responded to existing therapies.
The study tests three interventions: Lutikizumab monotherapy, Ravagalimab monotherapy, and a combination of Lutikizumab and Ravagalimab. These treatments are compared against placebos to assess their effectiveness in managing rheumatoid arthritis symptoms.
This interventional study utilizes a randomized, parallel assignment model with double masking for participants and investigators. Its primary purpose is treatment, focusing on evaluating the targeted therapies’ impact on rheumatoid arthritis.
The study began on June 20, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The study’s outcome could significantly influence AbbVie’s stock performance and investor sentiment, especially if the therapies prove effective. This development is particularly relevant in the competitive landscape of rheumatoid arthritis treatments, where new, effective solutions are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.